Keyprime Research
↗Cheongju, South Korea
Keyprime Research is a specialized Contract Research Organization (CRO) headquartered in Cheongju, South Korea. The company focuses on providing high-quality non-clinical research services, with a particular emphasis on toxicology and safety pharmacology studies utilizing non-human primate (NHP) models.
As part of the BTT (Biotoxtech) Group, Keyprime Research leverages advanced facilities and validated methodological approaches to support pharmaceutical and biotechnology companies in their drug development pipelines. They adhere to strict ethical standards and regulatory compliance, including 21 CFR Part 11, to ensure data integrity and reproducibility in translational research.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2021
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$14.9M
Investors:Company K Partners, DAYLI Partners, Envester, Eugene Investment & Securities, Honest Ventures
PIPELINE
Stage:Preclinical
Lead Drug Stage:N/A (Service Provider)
Modalities:Small molecule, Biologics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Biotoxtech Group
Key Partnerships:Biotoxtech Group (Affiliate), Various pharmaceutical and biotech sponsors
COMPETITION
Position:Niche Player
Competitors:Charles River Laboratories, Labcorp, WuXi AppTec, Envigo
LINKS
Website:keyprime.com
Crunchbase:Crunchbase Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Keyprime Research and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Keyprime Research. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.